Media coverage about OpGen (NASDAQ:OPGN) has trended somewhat positive on Tuesday, Accern Sentiment reports. The research group identifies positive and negative media coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. OpGen earned a daily sentiment score of 0.21 on Accern’s scale. Accern also gave news stories about the medical research company an impact score of 45.7356852225935 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
Shares of OpGen (OPGN) opened at $0.17 on Tuesday. The company has a current ratio of 1.23, a quick ratio of 1.13 and a debt-to-equity ratio of 0.03. OpGen has a fifty-two week low of $0.16 and a fifty-two week high of $1.85. The stock has a market capitalization of $9.46, a PE ratio of -0.27 and a beta of 0.96.
A number of analysts have recently issued reports on the company. Zacks Investment Research upgraded OpGen from a “hold” rating to a “buy” rating and set a $0.25 target price for the company in a report on Tuesday, November 14th. HC Wainwright reiterated a “buy” rating and set a $1.00 target price on shares of OpGen in a report on Tuesday, October 24th.
OpGen, Inc (OpGen) is a precision medicine company using molecular diagnostics and informatics to combat infectious disease. The Company is engaged in developing molecular information solutions to combat infectious disease in global healthcare settings, helping to guide clinicians with information about life threatening infections, managing patient outcomes, and the spread of infections caused by multidrug-resistant microorganisms.
What are top analysts saying about OpGen? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for OpGen and related companies.